Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

May

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

BPDCN FDA Approves Pivekimab Sunirine-pvzy

After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention

Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma

Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL

Early Breast Cancer Is Surgery Omission Possible Following Estrogen and Ablative Radiation Therapy